Nepal Treats First Cancer Patient With Homegrown CAR-T Cell Therapy
Nepal has achieved a landmark in advanced cancer care: doctors have for the first time treated a cancer patient using CAR-T cell therapy developed and produced inside the country.
The treatment was carried out through a collaboration between the Tribhuvan University Teaching Hospital in Kathmandu — Nepal's leading public teaching hospital — and the Center for Regenerative Medicine Nepal (CRM Nepal), a domestic medical research institution. On 11 Ashoj (late September), a patient suffering from acute lymphoblastic leukemia (ALL), a type of blood cancer, received the lab-grown CAR-T cells.
CAR-T cell therapy is an advanced form of immunotherapy. Doctors extract immune cells called T-cells from the patient's own body, genetically modify them in a laboratory so they can recognize and attack cancer cells — in this case targeting a marker called CD-19 found in some blood cancers — grow them in the lab, and then infuse them back into the patient.
According to CRM Nepal, the patient is currently in stable condition and recovering, with the medical team keeping them under regular monitoring to assess how well the cancer is controlled and how long the effect lasts. Dr. Anjan Shrestha, the hemato-oncologist who led the treatment team, said the breakthrough opens new possibilities for expanding advanced cancer care within Nepal. Dr. Sanjeevan Gautam, CRM Nepal's chief scientist, called the early results encouraging, noting that the CAR-T cell count in the patient's blood rose as expected.
The development could reduce the need for Nepali patients to travel to India or China for such advanced treatment — a major step for a country where cutting-edge therapies have long depended on expensive treatment abroad.
Source: SouryaOnline, News Dainik
Comments
Post a Comment